Enovis (FRA:C520) Inventories, Raw Materials & Components: €103 Mil (As of Mar. 2026)


FRA:C520 Enovis Corp FRA:C520
64 GF Score
Price €21.80
GF Value €42.46
! 6 Warning Signs
View Full Analysis

What is Enovis Inventories, Raw Materials & Components?

Enovis FRA:C520 +6.86% 64 Inventories, Raw Materials & Components is €103 Mil as of Mar. 2026. GuruFocus rates FRA:C520 with a GF Score™ of 64/100 and a GF Value™ of €42.46. The stock has 6 warning signs investors should review.

Enovis's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €103 Mil.

Enovis's quarterly raw materials declined from Sep. 2025 (€114 Mil) to Dec. 2025 (€103 Mil) but then increased from Dec. 2025 (€103 Mil) to Mar. 2026 (€103 Mil).

Enovis's annual raw materials increased from Dec. 2023 (€81 Mil) to Dec. 2024 (€95 Mil) and increased from Dec. 2024 (€95 Mil) to Dec. 2025 (€103 Mil).

Enovis Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Enovis's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis Inventories, Raw Materials & Components Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.14 94.44 80.81 95.15 103.02

Enovis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.57 87.87 113.66 103.02 103.13
FRA:C520
64GF Score
Enovis Corp FRA:C520
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enovis Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €103 Mil mean?
Enovis (FRA:C520) has a Inventories, Raw Materials & Components of €103 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Enovis and its competitors.
Is Enovis' Inventories, Raw Materials & Components too high?
Enovis' current Inventories, Raw Materials & Components is €103 Mil. Overall, Enovis has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Enovis' Inventories, Raw Materials & Components compare to INSP and PRCT?
Enovis' Inventories, Raw Materials & Components of €103 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Medical Devices & Instruments company?
A good Inventories, Raw Materials & Components depends on the Medical Devices & Instruments industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Enovis and its competitors. Enovis's current Inventories, Raw Materials & Components is €103 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Enovis (FRA:C520) has a current Inventories, Raw Materials & Components of €103 Mil. The stock's GF Value™ is €42.46, compared to a current price of €21.80 — trading 48.7% below its estimated fair value. The current Inventories, Raw Materials & Components is €103 Mil. Enovis' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Enovis (FRA:C520), the current Inventories, Raw Materials & Components is €103 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (FRA:C520) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of €21.80 is trading 48.7% below its estimated GF Value™ of €42.46.

Key valuation signals for FRA:C520:

  • Inventories, Raw Materials & Components: €103 Mil
  • GF Value™: €42.46 vs. price of €21.80 (48.7% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the FRA:C520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
64GF Score

Get the complete analysis for FRA:C520

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€42.46
GF Value